Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

completed250%
recruiting125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786
terminatedphase_2

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

NCT05879718
completedphase_1

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

NCT05037409
completedphase_1

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

NCT02766621

Clinical Trials (4)

Showing 4 of 4 trials
NCT05895786Phase 3

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Recruiting
NCT05879718Phase 2

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Terminated
NCT05037409Phase 1

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Completed
NCT02766621Phase 1

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4